These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
39 related articles for article (PubMed ID: 8104348)
21. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia. Naber D; Nedopil N; Eben E Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374 [TBL] [Abstract][Full Text] [Related]
22. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450 [TBL] [Abstract][Full Text] [Related]
23. Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia. Gaebel W; Müller-Oerlinghausen B; Schley J Prog Neuropsychopharmacol Biol Psychiatry; 1992; 16(6):891-900. PubMed ID: 1355303 [TBL] [Abstract][Full Text] [Related]
24. A therapeutic trial of caerulein to a long-term heavy marihuana user with amotivational syndrome. Watanabe N; Moroji T; Tada K; Aoki N Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(3):419-21. PubMed ID: 6148769 [TBL] [Abstract][Full Text] [Related]
25. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. Heres S; Cordes J; Feyerabend S; Schmidt-Kraepelin C; Musil R; Riedel M; Spellmann I; Langguth B; Landgrebe M; Fran E; Petcu C C; Hahn E; Ta TMT; Matei V; Dehelean L; Papava I; Leweke FM; van der List T; Tamasan SC; Lang FU; Naber D; Ruhrmann S; Wolff-Menzler C; Juckel G; Ladea M; Stefanescu C; Lautenschlager M; Bauer M; Zamora D; Horowitz M; Davis JM; Leucht S Schizophr Bull; 2022 Nov; 48(6):1273-1283. PubMed ID: 35857811 [TBL] [Abstract][Full Text] [Related]
26. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408 [TBL] [Abstract][Full Text] [Related]
27. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Tardy M; Huhn M; Kissling W; Engel RR; Leucht S Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009268. PubMed ID: 25007358 [TBL] [Abstract][Full Text] [Related]
29. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M; Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763 [TBL] [Abstract][Full Text] [Related]
30. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Haas S; Beckmann H Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498 [TBL] [Abstract][Full Text] [Related]
31. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients]. Dieterle DM; Müller-Spahn F; Ackenheil M Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334 [TBL] [Abstract][Full Text] [Related]
32. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. den Boer JA; Westenberg HG Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547 [TBL] [Abstract][Full Text] [Related]
33. Initial improvement as a criterion for drug choice in acute schizophrenia. Klimke A; Klieser E; Lehmann E; Miele L Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348 [TBL] [Abstract][Full Text] [Related]